Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib

Saved in:

Bibliographic Details
Published in:	Clinical breast cancer Vol. 14; no. 1; pp. e14 - e16
Main Authors:	Ali, Siraj M, Alpaugh, R. Kathy, Buell, Jamie K, Stephens, Philip J, Yu, Jian Qin (Michael), Wu, Hong, Hiemstra, Christine N, Miller, Vincent A, Lipson, Doron, Palmer, Gary A, Ross, Jeffrey S, Cristofanilli, Massimo
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-02-2014
Subjects:	Erlotinib Hydrochloride Female Hematology, Oncology and Palliative Medicine HER2 Humans Inflammatory breast cancer Inflammatory Breast Neoplasms - drug therapy Inflammatory Breast Neoplasms - genetics Inflammatory Breast Neoplasms - pathology Lapatinib Middle Aged Mutation Next-generation sequencing Obstetrics and Gynecology Protein Kinase Inhibitors - therapeutic use Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Trastuzumab Inflammatory breast cancer Next-generation sequencing Lapatinib HER2 Trastuzumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1526-8209 1938-0666
DOI:	10.1016/j.clbc.2013.09.010